Correct Answer: D. PDE 3 inhibition
Theophylline is a non-selective phosphodiesterase (PDE) inhibitor, but its diuretic effect is specifically mediated through PDE 3 inhibition in the kidney. PDE 3 inhibition increases intracellular cAMP in renal tubular cells, particularly in the collecting duct and thick ascending limb of the loop of Henle. Elevated cAMP leads to inhibition of aquaporin-2 water channel insertion and reduced sodium reabsorption, resulting in increased urine output. This is distinct from theophylline's bronchodilator effect, which primarily involves PDE 4 inhibition in airway smooth muscle. The diuretic action occurs at therapeutic doses used in Indian clinical practice (10–20 mg/kg/day), making it a clinically relevant side effect. While theophylline does have some adenosine antagonism, this contributes to CNS stimulation and cardiac effects rather than diuresis. The PDE 3 inhibition mechanism explains why theophylline can cause electrolyte disturbances (hypokalemia, hyponatremia) in patients on chronic therapy—a concern in elderly Indian patients with comorbidities.
Why the other options are wrong
A. Beta 2 agonism — This is wrong because theophylline is NOT a beta-2 agonist; it is a PDE inhibitor. While beta-2 agonists (like salbutamol) can cause mild diuresis through cAMP elevation in renal tissue, theophylline's mechanism is direct PDE inhibition, not adrenergic receptor activation. NBE may trap students who confuse theophylline's bronchodilation with beta-2 effects. B. Adenosine agonism — This is wrong because theophylline is an adenosine antagonist, not agonist. Adenosine antagonism causes CNS stimulation, tachycardia, and tremor—not diuresis. Adenosine agonists (like dipyridamole) have vasodilatory effects. This is a classic NBE trap: students may recall that theophylline blocks adenosine receptors but incorrectly link this to diuresis. C. PDE 4 inhibition — This is wrong because PDE 4 inhibition is the primary mechanism for theophylline's bronchodilation in airway smooth muscle, not diuresis. PDE 4 is abundant in inflammatory cells and airways. Renal diuresis is mediated by PDE 3 inhibition in collecting duct and loop of Henle cells. NBE exploits confusion between theophylline's respiratory vs. renal effects.
High-Yield Facts
- PDE 3 inhibition in renal collecting duct → ↑cAMP → aquaporin-2 inhibition → diuresis
- PDE 4 inhibition in airway smooth muscle → bronchodilation (primary therapeutic effect)
- Theophylline is a non-selective PDE inhibitor (inhibits PDE 1, 3, 4, 5); specificity depends on tissue distribution
- Adenosine antagonism by theophylline → CNS stimulation, tachycardia, tremor (not diuresis)
- Chronic theophylline use → hypokalemia, hyponatremia due to increased renal losses (Indian elderly at risk)
Mnemonics
PDE Tissue Selectivity PDE 3 = Kidney (Diuresis); PDE 4 = Airways (Bronchodilation). Remember: '3 for Kidneys, 4 for Airways.' Theophylline hits both, but the question asks specifically about diuresis. Theophylline's Triple Action PDE inhibition (cAMP↑) + Adenosine antagonism (stimulation) + Calcium mobilization (smooth muscle). For diuresis, focus on PDE 3 in kidney tubules.
NBE Trap
NBE pairs theophylline's well-known bronchodilator effect (PDE 4) with the question about diuresis, hoping students will select PDE 4 instead of recognizing that renal diuresis is mediated by PDE 3. The trap exploits incomplete understanding of tissue-specific PDE distribution.
Clinical Pearl
In Indian clinical practice, theophylline-induced diuresis is a significant concern in elderly patients with COPD on chronic therapy, especially those already on loop diuretics for heart failure. Monitoring serum potassium and sodium is essential to prevent arrhythmias and hyponatremic encephalopathy—a common complication in our population with polypharmacy and renal impairment.
_Reference: KD Tripathi Pharmacology Ch. 27 (Bronchodilators); Harrison Ch. 252 (Diuretics mechanism)_